Pharma and Biotech
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-24 | 179.90 | 7.70 | (0.10)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-25 | 200.70 | 16.25 | 1.06p | 42.6 | n/a | n/a | n/a | 0.0% |
30-Sep-26 | 225.13 | 31.33 | 2.89p | 15.6 | 0.1 | +174% | n/a | 0.0% |
Copyright © 2024 FactSet Research Systems Inc. All rights reserved.
Current | 1 week ago | 1 month ago | 3 months ago | 6 months ago | 1 year ago | |
---|---|---|---|---|---|---|
Revenue (£m) | ||||||
30-Sep-2024 | 180 | n/a | n/a | n/a | n/a | n/a |
30-Sep-2025 | 201 | n/a | n/a | n/a | n/a | n/a |
30-Sep-2026 | 225 | n/a | n/a | n/a | n/a | n/a |
Earnings | ||||||
30-Sep-2024 | n/a | n/a | n/a | n/a | n/a | n/a |
30-Sep-2025 | 1.06p | n/a | n/a | n/a | n/a | n/a |
30-Sep-2026 | 2.89p | n/a | n/a | n/a | n/a | n/a |
Dividend | ||||||
30-Sep-2024 | n/a | n/a | n/a | n/a | n/a | n/a |
30-Sep-2025 | n/a | n/a | n/a | n/a | n/a | n/a |
30-Sep-2026 | n/a | n/a | n/a | n/a | n/a | n/a |
Recommendations | ||||||
Strong Buy | 2 | 0 | 0 | 0 | 0 | 0 |
Buy | 1 | 0 | 0 | 0 | 0 | 0 |
Neutral | 1 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Brokers | 4 | 0 | 0 | 0 | 0 | 0 |
Average Rec | 8.12 | n/a | n/a | n/a | n/a | n/a |
Find out about IFRS and how this affects the financial infomation for all UK companies.
Currency | UK Pounds |
Share Price | 45.00p |
Change Today | -0.50p |
% Change | -1.10 % |
52 Week High | 48.00 |
52 Week Low | 34.00 |
Volume | 126,760 |
Shares Issued | 739.67m |
Market Cap | £332.85m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 2 |
Buy | 1 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 4 |
No dividends found |
Time | Volume / Share Price |
14:54 | 15,000 @ 45.40p |
14:51 | 25,000 @ 45.08p |
13:32 | 15,000 @ 43.20p |
13:32 | 11,245 @ 43.10p |
11:20 | 329 @ 42.20p |
Chair | Peter George |
CFO | Septima Maguire |
CEO | Trond Williksen |
You are here: research